Quratis Inc
348080
Company Profile
Business description
Quratis Inc operates as a developer of vaccines and therapies designed to treat tuberculosis. The company develops youth and adults tuberculosis vaccines, messenger ribonucleic acids, and other related immune-related vaccines.
Contact
306, 13, Teheran-ro 64-gil
Gangnam-gu
Seoul
KORT: +82 262047727
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
72
Stocks News & Analysis
stocks
Is this still an ASX share to own forever?
Find out how this defensive player has fared after earnings.
stocks
After earnings, is Nvidia stock a buy, a sell, or fairly valued?
No signs of a slowdown in demand for Nvidia’s chips, and the long-term picture looks bright.
stocks
Short-term pain for long-term gain for undervalued ASX share
Cost reductions lower our profit estimates but should lead to improved long-term outcomes.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,131.20 | 1.70 | 0.02% |
| CAC 40 | 7,698.92 | 20.79 | -0.27% |
| DAX 40 | 23,770.33 | 175.53 | 0.74% |
| Dow JONES (US) | 45,621.29 | 350.06 | 0.77% |
| FTSE 100 | 9,216.87 | 38.88 | 0.42% |
| HKSE | 25,165.29 | 106.78 | 0.43% |
| NASDAQ | 21,707.69 | 209.97 | 0.98% |
| Nikkei 225 | 42,915.45 | 335.18 | 0.79% |
| NZX 50 Index | 13,207.66 | 74.46 | 0.57% |
| S&P 500 | 6,502.08 | 53.82 | 0.83% |
| S&P/ASX 200 | 8,863.20 | 0.60 | 0.01% |
| SSE Composite Index | 3,763.11 | 2.76 | -0.07% |